SOMERSET, N.J. (PRWEB) July 16, 2019 Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA). Through this collaboration,…

Source link